Established in 2006, the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) continues to adapt to changing and challenging new threats to the public’s health. The COVID-19 pandemic illustrates the strain that new and emerging public health threats can have on the U.S. health system.
The PHEMCE will coordinate and collaborate with partners across the interagency to ensure that the needed medical countermeasures and associated capabilities are in place to protect the American people.
The PHEMCE considers the long-term needs of the medical countermeasures enterprise, including interagency funding, considers business process improvement, strategic engagement and coordination.
Business Process Improvement
| Create infrastructure to implement | 
| Establish a transparent biodefense industrial base policy |
|
Provide subject matter guidance on: ∙ Emergency Use Declarations
| 
|
∙ Manage process for
identifying health security needs
∙ Supporting alignment to address needs
|
Strategic Engagement & Coordination
| Manage:
∙ Portfolio Advisory Teams ∙ Senior Federal Officials
∙ Enterprise Governance Board ∙ Preparedness and Response
Requirements Oversight Council
| 
| Coordinate on:
∙ Program expenditures across
MCM agencies
|
|
Solicit input from SLT stakeholders
| 
|
Host the PHEMCE Stakeholders Workshops
|
Advise the HHS Secretary & the ASPR
|
Improve SLTT distribution & dispensing capabilities | 
| Facilitate replenishment of countermeasures |
|
Make recommendations that
advance research and
development
| 
|
∙ Determine product suitability
∙ Validate capability based and material requirements
|
Deliver Timely, Strategic Products
| Deliver:
∙ SNS Annual Review
| 
|
with other strategic plans
|
